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Abstract 
Background: Antiphospholipid Syndrome (APS) is a rare autoimmune disorder with an estimated prevalence of 
40–50 cases per 100.000 persons. Patients suffering from low prevalence diseases are more likely to face diagnostic 
challenges, given the limited knowledge of most clinicians. The main aim of this study was to investigate the time 
between symptoms occurrence and the diagnosis of APS patients using the Piedmont and Aosta Valley Rare Disease 
Registry. Secondly, to evaluate the individual impact of the diagnostic gap by gathering patients’ personal experiences 
through a self-administered questionnaire.
Results: Data from the Piedmont and Aosta Valley Rare Disease Registry was used. In addition, personal experi-
ences were analyzed through a self-administered questionnaire. A total of 740 APS patients included in the Piedmont 
and Aosta Valley Rare Disease Registry were analyzed. Diagnostic delay (as defined by time between symptoms’ 
occurrence and the diagnosis of APS) was significantly reduced over time. In particular, when comparing the diag-
nostic delay between patients diagnosed between 1983 and 1999 and patients diagnosed between 2000 and 
2015, we found a significant statistical difference (Mann-Whithey U Test; mean rank 1216.6 vs. 1066.9, respectively; 
p < 0.0001). When analyzing the self-administered questionnaires, patients with a perception of having suffered for 
a diagnostic delay had a higher prevalence of symptoms suggestive of an autoimmune condition but not highly 
suggestive of APS (45%), followed by “extra criteria” APS manifestation (30%) and by thrombotic events (25%). The 
first clinical manifestation of patients who did not have the perception of having suffered a diagnostic delay was 
thrombotic events (45.5%), followed by autoimmune manifestation not linked to APS (45.5%), and “extra criteria” APS 
manifestations (9%).
Conclusions: While the diagnostic delay of APS has been reduced during the last years, the time between symptoms 
occurrence and the diagnosis of rare diseases still represents a critical issue to be addressed in order to prevent major 
complications.
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Introduction
Antiphospholipid Syndrome (APS) is an autoimmune 
disorder characterized by thrombotic events and/or 
pregnancy morbidity (PM) in the presence of persistent 
presence of antiphospholipid antibodies (aPL) [1]. While 
APS is often referred as the most common acquired 
thrombophilia, the global incidence of APS is estimated 
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to be 5 cases per 100,000 persons per year, with an esti-
mated prevalence of 40–50 cases per 100,000 persons [2–
4]. Consequently, APS is listed among the rare diseases, 
defined according to both the European (prevalence less 
than or equal to 5 cases per 10,000 people) [5] and US 
(any disease or condition that affects fewer than 200,000 
people in the United States  or about 1 in 1500 people) 
definitions [6].
Recent studies [7, 8] have highlighted the limited 
knowledge of most clinicians when they face rare patho-
logical conditions. Consequently, patients suffering from 
low prevalence diseases are more likely to face diagnostic 
challenges, with the risk of encountering under diagno-
sis or delayed diagnosis. This might severely impact APS 
patients, as they might experience recurrence of throm-
bosis and/or PM episodes while waiting for a diagnosis 
and consequently an appropriate treatment.
The objective of our study was to analyze the diagnos-
tic delay (as defined by time between symptoms occur-
rence and the diagnosis of APS) based on data from the 
Piedmont and Aosta Valley Rare Disease Registry and by 




Data were collected from the Piedmont and Aosta Val-
ley Rare Disease Registry, as part of the National Registry 
of Rare Diseases, by the coordinating Center of Piedmont 
and Aosta Valley Network for Rare Diseases, S. Gio-
vanni Bosco Hospital, Turin, Italy. The Registry is based 
on a continously implemented  dataset, including socio-
demographic and disease data, as detailed elsewhere [11].
A total of 740 patients with a definite diagnosis of APS 
has been included in the Rare Disease Register of Pied-
mont and Aosta Valley over the last 35 years. Data of the 
Registry include age at first clinical manifestation of the 
patient and age of the patient at diagnosis.
Diagnostic delay questionnaires
A self-administered questionnaire was appositely 
designed to enquire the diagnostic delay in APS. The 
questionnaire was administered to APS patients fulfilling 
the current diagnostic criteria [1] and meeting the fol-
lowing characteristics: (1) with an active follow-up at the 
San Giovanni Bosco Hospital; (2) APS diagnosis within 
the last 5 years.
Due to a retrospective character of the study, there 
was a risk that the information given by the respond-
ents might not be exact. Therefore, for this part of 
the study, the authors took into consideration only 
patients who had been diagnosed within the last 5 years 
preceding the study or were undergoing diagnosis. This 
allowed to reduce the influence of time on the quality of 
the respondents information.
Questionnaires were filled out anonymously by 
the patients via Google Forms.  All patients signed 
an informed consent.  This study was conducted in 
compliance with the Declaration of Helsinki and was 
approved by the local ethical committee.
Results
Registry
Data from a total of 740 APS patients included in the 
Piedmont and Aosta Valley Rare Disease Registry was 
analyzed. Median age at diagnosis was 45 years old 
(Interquartile Range, IQR 34–57), while the median age 
of the first clinical manifestation of APS (either throm-
botic or pregnancy morbidity) fulfilling the diagnostic 
criteria of the disease [1] was 40 years old (IQR 29–52). 
The mean diagnostic delay was of 4.7 years (S.D. ±8.3), 
median 1 year (IQR 0–5).
Data was then stratified by time period, as shown in 
Fig.  1. Interestingly, the diagnostic delay was signifi-
cantly reduced over time, starting from data collected 
since 1983 (the year of APS description [10]), with 
a mean diagnostic delay of 3.4 years ± 5.2 (median 5 
years; IQR 3–10), since 1990 (mean diagnostic delay 3 
years ± 4.7; median 5, IQR 3–9), since 2000 (mean diag-
nostic delay 2.2 years ± 3.2; median 4, IQR 2–7), since 
2010 (mean diagnostic delay 1.1 years ± 1.4; median 3, 
IQR 3, 2-3.75) and since 2015 (mean diagnostic delay 
0.8 years ± 0.8; median 2, IQR 2, 2–3).
When comparing the diagnostic delay between 
patients diagnosed between 1983 and 1999 and patients 
diagnosed between 2000 and 2015, we found a signifi-
cant statistical difference (Mann-Whithey U Test; mean 
rank 1216.6 vs. 1066.9, respectively; p < 0.0001).
Fig. 1 Box plot of the diagnostic delay of antiphospholipid syndrome 
stratified by time period
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Questionnaire
Among the eligible patients, thirty-three patients (66% 
females; mean age at data collection 46.7 ± 13.2 years 
old) filled out the anonymous questionnaire via Google 
Forms. The rate of response to the questionnaire was 
(33/74, 45%). Seventeen patients (52%) were primary 
APS, while 16 patients (48%) had secondary APS. 
Twenty-four patients (73%) had at least one throm-
botic event, 6 patients experienced pregnancy morbid-
ity (3 recurrent miscarriages and 3 foetal deaths), and 
3 patients fulfilled the criteria for both thrombotic and 
obstetric APS.
When asked if, in their perception, there has been a 
delay when diagnosing their autoimmune condition, 20 
patients (61%) replied yes, 11 (33%) replied no and 2 (6%) 
were unsure of the reply. Of the patients that thought 
there had been indeed a diagnostic delay, the mean delay 
was of 46.5 months (S.D. ±65; max 240; min 3). When 
we asked these patients if their clinical manifestations, 
in light of their current disease knowledge, were sugges-
tive of APS, the majority of case (50%) answer yes, while 
30% were unsure and 20% believed that their first clinical 
manifestations were not linked to APS.
Interestingly, when looking at first clinical mani-
festations of autoimmune disease, the most common 
manifestation in patients that believed there had been a 
diagnostic delay was an autoimmune manifestation not 
linked to APS, as arthralgia and cutaneous manifestations 
(45%), followed by “extra criteria” APS manifestations, 
such as thrombocytopenia, hip osteonecrosis, migraine 
and livedo reticularis (30%) and by “criteria” manifesta-
tions such as thrombotic events (25%). In comparison, 
the first clinical manifestation of patients that did not 
believe there had been a diagnostic delay were “criteria” 
manifestations, such as thrombotic events and pregnancy 
complications (45.5%), followed by autoimmune manifes-
tation not linked to APS (45.5%), and “extra criteria” APS 
manifestation (9%).
When we focused on patients with referred diagnostic 
delay (20/33) and analyzed only those with a diagnostic 
lag of more than one year (8/20), we noticed that patients 
that waited the most (namely patient 1 and 2) were those 
with symptoms that emerged in the nineties, when APS 
knowledge was growing and sharpening. More in detail, 
patient 1 manifested first clinical sign in 1990 and was 
diagnosed in 2015; patient 2 had first clinical sign in 1998 
and was diagnosed in 2016. In case 1, the first symptom 
was a cutaneous rash, that was later classified as sys-
temic lupus erythematosus over time; in case 2 amnesia, 
migraine and digital petechiae manifested as first clinical 
signs, all now recognized “extra criteria” manifestations 
of APS.
When enquiring what was the reason the patients 
believed the delay was caused by, the majority of patients 
(16/20, 80%) thought that the doctor that first diagnosed 
them had been wrong or didn’t recognize the disease pro-
ceeding with further investigations. Two patients claimed 
of being misunderstood by the clinician and of having 
neglected their health issues contributing to the delay. All 
the reported answers are listed and resumed in Fig. 2.
When exploring the number of clinicians/centers con-
sulted before diagnosis was established, 26 patients (79%), 
with and without declared delayed diagnosis, reported 
of being evaluated by one to three different physicians. 
Seven patients (21%), nonetheless, consulted more than 
four different centers/physicians before receiving APS 
diagnosis. Respondents stated that the first clinician who 
suspected the disease was a specialized physician, but 
three subjects indicated their general practitioners as the 
first clinician to point it out.
Discussion
The delay of diagnosis represents one of the main chal-
lenges in the field of rare diseases. Patients affected 
by these conditions often have to wait months or 
years before having the right diagnosis. As previously 
reported, this is primarily due to a lack of knowledge of 
most clinicians, that are thus unable to recognize these 
pathologies, and also to a lack of time to work on these 
diagnoses [7]. The consequences on patients’ condi-
tions are serious. An early diagnosis of any rheumatic 
disease indeed has a significant impact on the effec-
tiveness of treatment, the reduction of disease activity 
and the chance of remission. For instance, in patients 
affected by rheumatoid arthritis there is a strong evi-
dence that a prompt diagnosis (in particular within 
three months from the symptoms onset) is associated 
with an improvement of the clinical and radiographic 
outcomes and also with a higher rate of remission [11].
Given this, in the last years, several attempts have 
been made in order to overcome the diagnostic delay in 
rare diseases, for instance the development of diagnosis 
support tools, automatic algorithms or methods based 
numerical scores [7].
With regard to APS, the analysis of the Rare Disease 
Registry of Piedmont and Aosta Valley highlighted a 
mean diagnostic delay of 4.7 years, that shortened to less 
than one year when considering the period 2015–2020.
These results were confirmed by the use of the self-
administered questionnaires, which underlined the per-
sistence of a temporal gap between the occurrence of first 
clinical sign and diagnosis, even if gradually reducing. It 
has to be noticed that both “criteria” and “extra criteria” 
manifestations were correlated with diagnostic delay [12]. 
Indeed, patients with “extra criteria” manifestations and 
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especially  those who  are positive for non criteria aPL, 
such as anti-phosphatidylserine/prothrombin antibodies, 
more likely face a delay in diagnosis or are at higher risk 
of been misdiagnosed [13].
As well as for the other rheumatic diseases, the impli-
cations of a prompt APS diagnosis are multiple. An early 
diagnosis allows rapid treatment and the  reduction/
avoidance of recurrent thrombotic and PM events, in 
patients that potentially are very young, impacting both 
on quality of life and permanent disability. Furthermore, 
correct identification of rare diseases patients is crucial 
as these patients might have the necessity of dedicated 
health plans, specialized care in tertiary care centers or 
dedicated exemptions from contribution to the health-
care expense.
Given this, even if it has been observed a reduction in 
APS diagnostic delay in the last years,  this  aspect still 
remains a main issue to be addressed. The time between 
the clinical manifestations’ onset and the diagnosis, and 
the risk of a misdiagnosis have to be further reduced, in 
order to avoid a delayed management of the patients that 
can be particularly damaging for their health. Indeed in 
our experience, even considering the limited sample size 
of our enquired cohort, patients had to consult multiple 
physicians to come to a defined diagnosis. With this in 
mind, national health systems might require the estab-
lishment and promotion of national and supranational 
networks for the study, identification, classification and 
sharing of knowledge on rare diseases, especially among 
clinicians  (both general practitioners and specialized 
physicians) [14].
Lastly, questionnaire respondents showed a clear will-
ing of building a critical consciousness on their disease, 
stressing the necessity of being educated and under-
stood by their physicians. The importance of a rich inter-
play between different physicians and, at the same time, 
between clinicians and patients had been addressed in 
other chronic conditions as systemic lupus erythemato-
sus [15], proving its efficacy in improving patients com-
pliance, quality of life and pain control, strengthening 
patient-physician relationship.
Some limitations should be acknowledged.  Data col-
lection in register-based studies suffers from many limi-
tations: necessary information may be unavailable, data 
collection is not performed by the researcher, confounder 
information is lacking, information on data quality might 
be missing andpotential risk of data dredging. All the 
above applied to our study. Similarly, no comparative data 
are available. Also, no analysis was made regarding the 
respondent’s place of residence (village/city). The authors 
did not analyse the distance the patient had between the 
hospital and the place of residence. The before mentioned 
methodological limitations, however, concern most stud-
ies (both single- and multi-centre ones).
While the diagnostic delay of APS has been reduced 
during the last years, it is still an important issue that 
remains to be addressed when it comes to low prevalence 
diseases. Joint international efforts are needed in order to 
I don't know
The doctor didn't recognize the
disease
The doctor did not recognize the
disease and did not consider it
necessary to carry out further
investigations
I underestimated my health
problems
I felt I was being missunderstood by
the doctors
Fig. 2 Relative representations of reasons listed by the patients of the delay in diagnosing their condition
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